We are live on ! Find out more

FBRX

Forte Biosciences

FBRX

Delisted

FBRX was delisted on the 26th of August, 2026.

Back to rankings

About: Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Employees: 23

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.5%

Neutral 54.5%

Negative 0%

Alger Small Cap Growth Fund Q2 2026 Portfolio Review

Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the second quarter of 2026. Nebius Group, Astera Labs, Inc., and Twist Bioscience Corp. were among the top contributors to performance. Insmed Incorporated, Planet Fitness, Inc., and Forte Biosciences Inc. were among the top detractors from performance.

Alger Small Cap Growth Fund Q2 2026 Portfolio Review

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash. Halper Sadeh encourages Forte shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Forte and its board of directors violated the federa.

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance. During the quarter, Credo shares contributed positively to performance as investors responded favorably to the company's rapid revenue growth and rising demand from hyperscale customers. Karman Holdings Inc., GeneDx Holdings Corp., and Forte Biosciences Inc. were among the top detractors from performance.

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.

Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX)

NEW YORK, July 27, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Forte Biosciences, Inc. (NASDAQ: FBRX ) related to its sale to argenx BV.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX)

Proactive Investors

Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.

Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B

See News Rankings

Price charts implemented using Lightweight Charts™